Sjögren's disease is an autoimmune disease most characterized by symptoms like dry eyes and dry mouth, resulting from immune inflammation of the lacrimal and salivary glands. Researchers at the National Institutes of Health (NIH), led by Dr. Blake Warner, are studying tofacitinib, an oral medication, in adults with Sjögren's disease. The goal of this research study is to explore potential new treatment options and support the Sjögren's community. Tofacitinib is already approved by the United States Food and Drug Administration (FDA) for other autoimmune conditions and is being used investigationally in this research study.
What Does Participation Involve?
- Physical exam with blood and urine tests
- EKG and questionnaires
- Saliva sample collection B
- Taking tofacitinib by mouth twice daily at home
- Nine clinic visits over approximately 28 weeks
Who May Be Eligible?
- Adults 18–75 years old
- Diagnosed with Sjögren's disease
- Enrolled in NIH protocol 15-D-0051
Other Information
- Participation is voluntary
- All study-related care is provided at no cost
- Compensation may be provided
For More Information
NIH Clinical Center Office of Patient Recruitment
833-JOIN-NIH
TTY users dial 7-1-1
Email: ccopr@nih.gov
Or go online
Refer to NIH study # 002290-D
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Institute of Dental And Craniofacial Research (NIDCR)